Loading clinical trials...
Loading clinical trials...
A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
Conditions
Interventions
MenACWY-CRM
Locations
11
Germany
Dr. Johannes Kandzora and Dr. Kathrin Kandzora
Am Teich 11, Neumuenster, Germany
Bogda-Maria Kniese,
Boyneburgstr 7, Eschwege, Germany
Dr Goertz Martin Kimmig
GroBbottwarer Str 47, Oberstenfeld, Germany
Dr med Walter Otto
Heinrichstrasse 16 A, Fulda, Germany
Dr med Kerstin Pscherer
Hellersdorfer Str 237, Berlin, Germany
Dr Renate Mangelsdorf-Taxis
Kirchstrasse 2, Bonnigheim, Germany
Start Date
May 1, 2011
Primary Completion Date
September 1, 2011
Completion Date
September 1, 2011
Last Updated
June 18, 2018
NCT01725217
NCT03694405
NCT04358731
NCT01896596
NCT02811120
NCT03089086
Lead Sponsor
Novartis Vaccines
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions